Focus on the development and production of animal cell serum-free medium in the field of biopharmaceuticals
It is reported that biotechnology company “Beiji” announced the completion of tens of millions of yuan of round B financing, the investor is the National Small and Medium Enterprise Development Fund managed by Oriental Fuhai. This round of financing is mainly used for capacity expansion, product line development, R&D iteration and market expansion.
The public information shows that Becky has completed two rounds of financing, and completed the round A financing in 2016, the investor is Shanghai Science Investment. In 2018, the A+ round of investment was completed, and the investor was Shanghai Qingyi.
Beiji is mainly engaged in the research and development of animal cell serum-free medium in the field of biopharmaceuticals. It is a pilot incubation and industrialization of biomedical products such as antibodies, recombinant proteins, human and poultry virus vaccines, cell therapy and human tissue engineering. And industrial production provides technical support and key raw materials and equipment support.
Application range of 谙 谙 产品 products
Animal cell serum-free medium development and production technology, mainly serving biomedical enterprises. At present, the companies served by Becky have covered more than 20 provinces and cities such as Shanghai, Zhejiang, Beijing and Guangdong. They have obtained one new drug certificate for the service enterprise, two new veterinary drug certificates, and nearly 20 clinical projects underway.
The company has the technical services and process development capabilities of more than 10 antibody vaccine products and more than 8 antibody vaccine companies, and has an internationally advanced, low-temperature culture with an annual production capacity of 10 million liters. Basic dry powder production line.
DrivingM’s core product, the DrivingM series, is a serum-free culture with independent intellectual property rights developed for different cells such as blood cells, CHO, hybridoma, PK15, MDCK, MDBK, HEK293, BHK, Vero, and insect cells. base. The product supports high-density culture and high-efficiency expansion of cells, increasing the certainty of cell culture, while reducing production costs by one-third to one-half.
In the core team, Tan Wensong, founder and chairman of the company, is a professor at East China University of Science and Technology. The founding team is based on the talents of the Animal Cell and Tissue Engineering team of East China University of Science and Technology, and has three in the field of animal cell culture and bioreactor engineering. Ten years of technology and application accumulation. In addition, the company also introduced a packageA number of high-level talents, including experts in animal cell culture processes at the University of Minnesota, have joined the company. Currently, the company has more than 20 research and development teams. Production management and brand promotion personnel, worked in the United States 3M, Pfizer and other companies.